Skip to Main Content


Smilow Cancer Hospital and Yale Cancer Center receive grant from Frederick A. DeLuca Foundation to fund Hematology Research Center

April 24, 2019

Yale Cancer Center (YCC) and Smilow Cancer Hospital (SCH) are proud to announce a five-year grant awarded by The Frederick A. DeLuca Foundation to establish The DeLuca Center for Innovation in Hematology Research. The gift will help translate groundbreaking research discoveries into practice-changing improvements in clinical care for blood cancer patients at YCC and SCH. It will also ensure detailed genetic characterization of each patient’s cancer and advance the next generation of treatments for hematologic malignancies.

“We are so appreciative of this extremely generous and transformative gift from the DeLuca Foundation to help our team drive innovative research in blood cancers,” said Charles S. Fuchs, MD, MPH, director of YCC and Physician-in-Chief of SCH. “The DeLuca Center marks a bold, new initiative at YCC and SCH that will accelerate cancer research and strengthen our battle against hematologic malignancies.”

Hematologic malignancies (leukemia, lymphoma, multiple myeloma and related cancers) represent a major contributor to the burden of cancer in the U.S. and across the world.

“My husband Fred battled Leukemia, so I experienced first-hand the devastating impact blood cancers can have on individuals and families,” said Elisabeth DeLuca, president of The Frederick A. DeLuca Foundation. “While there has been progress in the development of new treatments for these cancers, there remains a critical need for new, more effective therapies that can meaningfully improve the outcome for patients. It is my wish that The DeLuca Center for Innovation in Hematology Research will develop cutting-edge therapies to enhance the lives of blood cancer patients.”

The funding for the new center will also help establish a biobank and foster the development of young investigators who will advance the next generation of treatments for leukemia and other hematologic malignancies.

Submitted by Anne Doerr on April 24, 2019